Literature DB >> 26526065

Ketamine administration diminishes operant responding but does not impair conditioned fear.

Caitlin M Groeber Travis1, Daniel E Altman2, Raymond F Genovese2.   

Abstract

While not well understood, the NMDA (N-methyl-D-aspartate) antagonist ketamine, a dissociative anesthetic, has been reported to be efficacious in depression and related psychological disorders. Conditioned fear is a normal emotional conditioning process that is known to become dysfunctional in individuals suffering from Post-Traumatic Stress Disorder (PTSD) and related stress disorders. We examined the effects of ketamine to determine the potential modulation of the acquisition and extinction of a conditioned fear using a conditioned suppression procedure. Rats were trained on a variable interval (VI), food maintained, operant conditioning task to establish a general measure of performance. Rats were exposed to inescapable shock (IES, unconditioned stimulus) paired (×20) with an audio/visual conditioned stimulus (CS) to establish conditioning. Conditioning was quantified by measuring response suppression following CS presentation during subsequent extinction trials where the CS alone was presented. Ketamine or vehicle was administered either after initial conditioning or after each of the subsequent extinction trials. For each regimen, a series of four injections were administered 60 min apart (100, 50, 50, 50 mg/kg, respectively) in order to sustain a ketamine effect for a minimum of 4 h. Ketamine produced a general decrease in responding on the VI, relative to baseline, as response rates were slower on the operant task when tested 24 h later and longer. Ketamine did not affect the acquisition of the conditioned fear when the regimen was administered shortly after the initial pairings of IES and CS. Ketamine did not alter extinction to the conditioned fear when the regimen was administered following each CS only presentation following initial conditioning. Our conclusion from these findings is that while ketamine alters behavior on an appetitively motivated operant task it does not, however, appear to directly modulate learning and memory processes associated with conditioned fear.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conditioned fear; Conditioned suppression; Ketamine; Operant conditioning; PTSD; Stress processes

Mesh:

Substances:

Year:  2015        PMID: 26526065     DOI: 10.1016/j.pbb.2015.10.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  5 in total

Review 1.  Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.

Authors:  Liana Fattore; Alessandro Piva; Mary Tresa Zanda; Guido Fumagalli; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

2.  Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine.

Authors:  Florian Duclot; Iara Perez-Taboada; Katherine N Wright; Mohamed Kabbaj
Journal:  Neuropharmacology       Date:  2016-06-22       Impact factor: 5.250

3.  The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.

Authors:  Ling-Sha Ju; Jiao-Jiao Yang; Lei Lei; Jiang-Yan Xia; Dan Luo; Mu-Huo Ji; Anatoly E Martynyuk; Jian-Jun Yang
Journal:  Front Cell Neurosci       Date:  2017-04-20       Impact factor: 5.505

4.  Enhanced fear memories and brain glucose metabolism (18F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats.

Authors:  Kennett D Radford; Thomas Y Park; Shalini Jaiswal; Hongna Pan; Andrew Knutsen; Michael Zhang; Mercedes Driscoll; Lisa A Osborne-Smith; Bernard J Dardzinski; Kwang H Choi
Journal:  Transl Psychiatry       Date:  2018-11-30       Impact factor: 6.222

5.  The effect of ketamine on the consolidation and extinction of contextual fear memory.

Authors:  Nicholas E Clifton; Kerrie L Thomas; Jeremy Hall
Journal:  J Psychopharmacol       Date:  2018-01-17       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.